Elocom

Package Leaflet: Information for the User

Warning! The leaflet must be kept. Information on the immediate packaging in a foreign language.

Elocom (Елоком)

1 mg/g (0.1%), cream

Mometasone furoate
Elocom and Елоком are the same trade names for the same drug written in Polish and Bulgarian.

Before using the medicine, you should carefully read the contents of the leaflet, as it contains important information for the patient.

• The leaflet should be kept so that it can be re-read if necessary.
• In case of any doubts, you should consult a doctor or pharmacist.
• This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same.
• If the patient experiences any side effects, including any side effects not listed in this leaflet, they should inform their doctor, pharmacist, or nurse. See section 4.

Table of Contents of the Leaflet

• 1. What is Elocom and what is it used for
• 2. Important information before using Elocom
• 3. How to use Elocom
• 4. Possible side effects
• 5. How to store Elocom
• 6. Contents of the packaging and other information

1. What is Elocom and what is it used for

Elocom cream contains the active substance mometasone furoate. Mometasone furoate is a synthetic corticosteroid with strong action; when used locally, it has anti-inflammatory, antipruritic, and vasoconstrictive effects.
Elocom cream is indicated for the relief of inflammatory and pruritic symptoms in corticosteroid-responsive skin diseases, such as psoriasis and atopic dermatitis.

2. Important information before using Elocom

When not to use Elocom:

• if the patient is allergic to mometasone furoate, other corticosteroids, or any of the other ingredients of this medicine (listed in section 6);
• in acne vulgaris;
• in rosacea;
• in skin atrophy;
• in perioral dermatitis;
• in bacterial infections (e.g., impetigo, pyoderma), viral infections (e.g., herpes simplex, chickenpox, and shingles, common warts, molluscum contagiosum), parasitic infections, and fungal infections of the skin (e.g., caused by dermatophytes or yeasts);
• in post-vaccination reactions;
• in cutaneous tuberculosis;
• on syphilitic skin lesions;
• in anal and genital pruritus;
• in diaper dermatitis;
• on damaged and ulcerated skin.

Warnings and precautions

Before starting to use Elocom, you should discuss it with your doctor or pharmacist.
If symptoms of irritation or allergy occur after using the medicine, you should contact your doctor immediately.
In case of infections, the doctor will use appropriate antibacterial or antifungal treatment. If there is no rapid and positive response to treatment, the use of the corticosteroid should be discontinued until the infections are cured.
Due to the increased risk of systemic side effects of corticosteroids, Elocom should be avoided on large areas of the body, under dressings, for prolonged periods, and on the face and skin folds, as well as in children. If it is necessary to apply the medicine to the face, treatment should not last more than 5 days.
Any side effects reported after using systemic corticosteroids, including adrenal suppression, may also occur with topical corticosteroids, especially in infants and children.
Children are more likely to experience systemic side effects of corticosteroids, such as adrenal suppression and Cushing's syndrome, due to their larger body surface area to body mass ratio.
The medicine should not be used on skin covered with a diaper, as it may act like a dressing and increase the percutaneous absorption of mometasone furoate.
The smallest effective dose of the medicine should be used, allowing for the relief of disease symptoms, especially in children. Long-term treatment with corticosteroids may affect the growth and development of children.
Elocom is not intended for ophthalmic use (including the eyelids) due to the very rare risk of developing glaucoma or subcapsular cataract.
Patients with psoriasis should use the medicine with caution.
Using the medicine in psoriasis may cause a relapse of the disease due to the development of tolerance, the occurrence of generalized pustular psoriasis, and general toxic effects related to skin continuity disorders.
As with other potent topical corticosteroids, sudden discontinuation of treatment should be avoided. After sudden discontinuation of the medicine, severe redness, burning, and stinging (so-called "rebound effect") may occur. In such cases, you should contact your doctor.
Elocom, like other medicines containing corticosteroids, may change the appearance of some skin lesions, making it difficult for the doctor to diagnose, and may also delay healing.
You should consult your doctor, even if the above warnings refer to situations that have occurred in the past.
If the patient experiences blurred vision or other vision disturbances, they should contact their doctor.

Elocom and other medicines

No data available.
You should tell your doctor or pharmacist about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your doctor or pharmacist before using this medicine.
Pregnancy
The safety of using Elocom during pregnancy has not been established.
Elocom can be used during pregnancy only if the doctor believes that the benefits to the mother outweigh the potential risks to the mother and fetus. However, the medicine should not be used on large areas of the body or for extended periods. Animal studies have shown that corticosteroids may harm the fetus.
Breastfeeding
It is not known whether topically administered corticosteroids are absorbed through the skin in sufficient amounts to pass into breast milk.
The use of Elocom by breastfeeding women is possible only if the doctor decides to do so after careful consideration of the risk of side effects in children versus the benefits of treatment for the mother.
If the doctor considers long-term therapy necessary, breastfeeding should be discontinued.

Driving and using machines

Elocom does not affect the ability to drive or use machines.

3. How to use Elocom

This medicine should always be used as directed by your doctor. If you are unsure, you should consult your doctor or pharmacist.
Affected areas of the skin are usually treated with a thin layer of cream once a day.
The use of cream is recommended for the treatment of dry, scaly, and cracked skin.
If you feel that the effect of the medicine is too strong or too weak, you should consult your doctor.

Use in children

Elocom should be used with caution in children over 2 years of age, although the safety and efficacy of Elocom have not been studied for more than 3 weeks.
There is insufficient data on the use of the medicine in children under 2 years of age.
The smallest effective dose of the medicine should be used, allowing for the relief of disease symptoms.
Long-term treatment with corticosteroids may affect the growth and development of children.

Using a higher dose of Elocom than recommended

No cases of overdose have been reported to date.
Prolonged topical use of corticosteroids may lead to adrenal suppression and subsequent adrenal insufficiency.
In case of overdose, the doctor will use appropriate symptomatic treatment and supportive therapy. Acute symptoms of corticosteroid overdose are usually reversible. In case of chronic poisoning, the doctor will recommend gradual withdrawal of the medicine.

Missing a dose of Elocom

A double dose should not be used to make up for a missed dose.

4. Possible side effects

Like all medicines, Elocom can cause side effects, although not everybody gets them.
The following side effects have been observed during the use of topical corticosteroids:

• Very rare (occurring in less than 1 in 10,000 patients): folliculitis, burning sensation, pruritus.
• Frequency not known (cannot be estimated from the available data): infections, furuncles, paresthesia, contact dermatitis, hypopigmentation, hypertrichosis, striae, acneiform eruptions, skin atrophy, pain at the application site, reactions at the application site, blurred vision.

After using the medicine on a large area of skin for a long time, especially with occlusive dressings, systemic absorption of the medicine has been observed.
The following side effects have been observed during the use of topical corticosteroids: dry skin, skin irritation, dermatitis, perioral dermatitis, skin maceration, and the occurrence of widened small blood vessels (telangiectasias).

Reporting side effects

If you experience any side effects, including any side effects not listed in the leaflet, you should inform your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
tel.: +48 (22) 49 21 301
fax: +48 (22) 49 21 309
Website: https://smz.ezdrowie.gov.pl
By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Elocom

The medicine should be stored out of sight and reach of children.
Store at a temperature below 25°C.
Shelf life after first opening the packaging: 1 month.
Do not use damaged or opened packaging.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the specified month.
Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the packaging and other information

What Elocom contains

• The active substance of the medicine is mometasone furoate. 1 gram of cream contains 1 mg of mometasone furoate.
• The other ingredients are: hexylene glycol, purified water, phosphoric acid, propylene glycol stearate, white wax, white petrolatum. This medicine contains 20 mg of propylene glycol stearate per gram of cream, which corresponds to 300 mg of propylene glycol stearate per unit (15 g tube) or 600 mg of propylene glycol stearate per unit (30 g tube).

What Elocom looks like and contents of the packaging

Elocom is a cream.
Packaging of the medicine
Aluminum tube with LDPE cap or laminated tube with HDPE head and PP cap, containing 15 g or 30 g of cream, placed in a cardboard box.
For more detailed information, you should contact the marketing authorization holder or parallel importer.

Marketing authorization holder in Bulgaria, the country of export:

N.V. Organon
Kloosterstraat 6
5349 AB Oss
Netherlands

Manufacturer:

Organon Heist bv
Industriepark 30
2220 Heist-op-den-Berg
Belgium

Parallel importer:

Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111, 91-222 Łódź

Repackaged by:

Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111, 91-222 Łódź
License number in Bulgaria, the country of export: 9700329

Parallel import license number: 429/15

Date of leaflet approval: 18.06.2025

[Information about the trademark]